Compounds of the formula (I); wherein R<1> is a member selected from the group consisting of C1-C8alkyl, arylC0-C8alkyl, C3-C12cycloalkyl and heterocyclyl, Y<1> is selected from the group consisting of a bond, C(R<5>)2, NR<5> and O; Y<2> is selected from the group consisting of a bond, NR<5> and O; each R<2>, R<3> and R<5> is independently selected from the group consisting of H, alkyl and COR<6>; A is heterocyclyl, optionally substituted with from 1 to 2 R<7> substituents; L is selected from the group consisting of a direct bond, C1-C12alkylene, C1-C12heteroalkylene, C3-C6cycloalkylene, arylene, heteroarylene, -CO-, -SOin- and -Se-; R<4> is selected from the group consisting of H, C1C8alkyl, C2-C6alkenyl, C2-C6alkynyl, C1,-C8heteroalkyl, arylC0-C8alkyl, C3C,12cycloalkyl and heterocyclyl, are claimed. The compounds are inhibitors of the soluble epoxide hydrolase (sEH) and useful for the treatment of hypertension, inflammation, adult respiratory distress syndrome; diabetic complications; end stage renal disease; Raynaud syndrome and arthritis.